# Employing a Combination of Chemoattractants to Trap Glioblastoma Cells in a Macroporous Hydrogel

**Authors:** Sahar Naasri, Hélène Therriault, Lisa Delattre, Nick Virgilio, Marc-Antoine Lauzon, Nathalie Faucheux, Benoit Paquette

PMC · DOI: 10.3390/pharmaceutics18020229 · 2026-02-11

## TL;DR

This study explores using a hydrogel trap to attract and retain glioblastoma cells by testing different cytokine combinations to enhance cell migration.

## Contribution

The study identifies a novel cytokine combination (IL-1β + CXCL12 + EGF) that effectively attracts diverse glioblastoma cell lines into a hydrogel trap.

## Key findings

- The cytokine combination IL-1β + CXCL12 + EGF was most effective in promoting migration of four GBM cell lines.
- U118 cells showed the best accumulation in the macroporous hydrogel when exposed to this cytokine combination.
- EGF induced epithelial–mesenchymal transition in all tested GBM cells, facilitating migration.

## Abstract

Background: A new paradigm for treating glioblastoma multiforme (GBM) cells was proposed. Instead of trying to eliminate cancer cells infiltrated in the brain, this new treatment is based on attracting them into a macroporous gel-based trap, where they are retained and then irradiated with a localized, higher radiation dose. The objective of this study is to identify a cytokine combination that would attract GBM cells while considering heterogeneity among GBM cell lines. Methods: The ability of different combinations of cytokines CXCL12, IL-1β, IL-6, and EGF to stimulate the migration of the GBM cell lines U87, U87 CXCR4+, F98, and U118 was assessed with a two-layer Matrigel device that simulates the extracellular environment in brain. The accumulation of GBM cells within a cancer cell trap made from a macroporous hydrogel consisting of 1% alginate, 0.75% chitosan, and 0.05% genipin was determined. This hydrogel was grafted with RGD and features fully interconnected pores with an average diameter of 300 µm. CXCL12 is the most frequently used for attracting GBM cells. The other cytokines were chosen to enhance CXCR4 expression, the receptor for CXCL12, increase matrix metalloproteinase-2 and -9 (MMP-2 and -9) production, and promote the epithelial–mesenchymal transition (EMT), a phenotype shift that facilitates cell migration. Results: IL-1β significantly enhanced CXCR4 expression in the F98 and U118 cells. The production of MMP-2 was significantly stimulated with IL-1β and IL-6 in F98 cells. The combination of the cytokines IL-1β + IL-6 + CXCL12 + EGF, on the other hand, induced a decrease in MMP-2 levels. The EMT was induced by EGF in all GBM cells tested. The results obtained using the two-layer Matrigel device showed that the combination of the cytokines IL-1β + CXCL12 + EGF was the most effective in promoting the migration of the four GBM cell lines. Regarding accumulation in the macroporous hydrogel, U118 cells showed the best response to this cytokine combination. Conclusions: A significant challenge in developing a cancer cell trap is to identify a cytokine combination to attract the heterogeneous population of GBM cells. In this study, the cytokine combination IL-1β + CXCL12 + EGF was found to be the most effective in promoting the migration of GBM cells.

## Linked entities

- **Proteins:** CXCL12 (C-X-C motif chemokine ligand 12), IL1B (interleukin 1 beta), IL6 (interleukin 6), EGF (epidermal growth factor), CXCR4 (C-X-C motif chemokine receptor 4), MMP2 (matrix metallopeptidase 2), MMP9 (matrix metallopeptidase 9)
- **Chemicals:** alginate (PubChem CID 5102882), chitosan (PubChem CID 129662530), genipin (PubChem CID 442424), RGD (PubChem CID 104802)
- **Diseases:** glioblastoma multiforme (MONDO:0018177), GBM (MONDO:0018177)

## Full-text entities

- **Genes:** CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, PSMC4 (proteasome 26S subunit, ATPase 4) [NCBI Gene 5704] {aka MIP224, RPT3, S6, TBP-7, TBP7}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 81686], Egf (epidermal growth factor) [NCBI Gene 25313], TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, L3MBTL2 (L3MBTL histone methyl-lysine binding protein 2) [NCBI Gene 83746] {aka H-l(3)mbt-l, L3MBT}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, VMA12 (vacuolar ATPase assembly factor VMA12) [NCBI Gene 147007] {aka C17orf32, CDG2P, TMEM199, VPH2}, RAPGEF5 (Rap guanine nucleotide exchange factor 5) [NCBI Gene 9771] {aka GFR, MR-GEF, MRGEF, REPAC}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688] {aka AGM10, OF, PU.1, SFPI1, SPI-1, SPI-A}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687], YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) [NCBI Gene 7534] {aka 14-3-3-zeta, HEL-S-3, HEL-S-93, HEL4, KCIP-1, POPCHAS}, PLP2 (proteolipid protein 2) [NCBI Gene 5355] {aka A4, A4LSB}, PUM1 (pumilio RNA binding family member 1) [NCBI Gene 9698] {aka HSPUM, NEDMSF, PUMH, PUMH1, PUML1, SCA47}, MRPL19 (mitochondrial ribosomal protein L19) [NCBI Gene 9801] {aka L15mt, L19mt, MRP-L15, MRP-L19, RLX1, RPML15}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 24772] {aka Sdf1}, VIM (vimentin) [NCBI Gene 7431], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, VAMP7 (vesicle associated membrane protein 7) [NCBI Gene 6845] {aka SYBL1, TI-VAMP, TIVAMP, VAMP-7}, Egf (epidermal growth factor) [NCBI Gene 13645], Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 60628], PLP1 (proteolipid protein 1) [NCBI Gene 5354] {aka GPM6C, HLD1, MMPL, PLP, PLP/DM20, PMD}
- **Diseases:** brain tumor (MESH:D001932), GBM (MESH:D005909), metastases (MESH:D009362), glioma (MESH:D005910), injury to (MESH:D014947), cancer (MESH:D009369)
- **Chemicals:** lipid (MESH:D008055), cysteine (MESH:D003545), PFA (MESH:C003043), polybrene (MESH:D006583), PLA (MESH:C033616), chloroform (MESH:D002725), polystyrene (MESH:D011137), glutamine (MESH:D005973), CO2 (MESH:D002245), Calcium (MESH:D002118), DAPI (MESH:C007293), AMD11070 (MESH:C494414), gemcitabine (MESH:D000093542), PBS (MESH:D007854), RGD (MESH:C047981), penicillin (MESH:D010406), puromycin (MESH:D011691), SA (MESH:D000077145), genipin (MESH:C007834), Dulbecco's modified Eagle's medium (-), amine (MESH:D000588), AMD (MESH:D008750), TMZ (MESH:D000077204), phenol (MESH:D019800), water (MESH:D014867), hyaluronic acid (MESH:D006820), cyclohexane (MESH:C506365), CaCl2 (MESH:D002122), Alg (MESH:D000464), PS (MESH:D010758), Chit (MESH:D048271), blasticidin (MESH:C004500), polymer (MESH:D011108), streptomycin (MESH:D013307), N2 (MESH:D009584), polysaccharides (MESH:D011134)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** T2A
- **Cell lines:** U87 WT — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_3429), LN992 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_6845), LN427 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_6841), U87 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), F98 — Rattus norvegicus (Rat), Rat malignant glioma, Cancer cell line (CVCL_3510), LN827 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_6843), U118 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0633), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), U87 CXCR4 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_X632)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944073/full.md

---
Source: https://tomesphere.com/paper/PMC12944073